Trimetazidine: potential mechanisms of action in hypertrophic cardiomyopathy.
作者信息
D'hahan N
机构信息
Département de Biologie Cellulaire et Moléculaire, CEA-Saclay, Gif-sur-Yvette, France.
出版信息
J Cardiovasc Pharmacol. 1999 Mar;33(3):500-6. doi: 10.1097/00005344-199903000-00022.
Abstract
In this review we consider available information on the cardio- and cytoprotective properties and mechanism of action of trimetazidine, an antianginal drug. Two points in particular are addressed: the advantages of trimetazidine over classic drugs and its possible use for the long-term treatment of hypertrophic cardiomyopathy, described as an ischemic disorder.
摘要
Zotero 插件